Why the study?
Does bivalirudin using adult dosing provide safe and predictable anticoagulation in pediatric patients undergoing intravascular procedures for congenital heart disease?
Does bivalirudin using adult dosing provide safe and predictable anticoagulation in pediatric patients undergoing intravascular procedures for congenital heart disease?
Bivalirudin using adult dosing is a safe and predictable anticoagulant for pediatric patients undergoing catheterization for congenital heart disease.
May support adult bivalirudin dosing in pediatric CHD catheterization; hypothesis-generating and requires randomized confirmation.
PK/PD response of bivalirudin in the pediatric population is predictable and behaves in a manner similar to that in adults. Using adult dosing, bivalirudin safely provided the expected anticoagulant effect in the pediatric population undergoing intravascular procedures for congenital heart disease.
No takes yet. Share an insight, caveat, or question.
Forbes et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: